Dr. Reddy'S Labs Peer Comparison

NSE: DRREDDY | BSE: 500124

₹1,233.00

₹14.20 (1.17%)

As on 16-Oct-2026IST

Market cap

₹1,02,820 Cr

Revenue (TTM)

₹33,228 Cr

P/E Ratio

31.9

P/B Ratio

2.7

Div. Yield

0.6 %

Edit

	Dr. Reddy'S Labs	Zydus Lifesciences	Aurobindo Pharma	Mankind Pharma	Lupin
Market cap (₹ Cr)	1,02,820	1,12,149	95,513	93,968	89,437
Revenue (₹ Cr)	33,228	28,592	34,935	14,738	29,967
Net Profit (₹ Cr)	3,169.30	4,492.20	3,712.74	2,055.11	5,551.01
Net Margin (%)	9.15	14.92	10.42	13.64	18.23
RoE (%)	8.72	18.78	10.38	13.60	28.32
Price to Earnings	31.91	24.85	25.73	46.00	16.18
Price-To-Book	2.69	4.16	2.45	5.58	3.76

Income Statement (₹ Cr)

	Dr. Reddy'S Labs	Zydus Lifesciences	Aurobindo Pharma	Mankind Pharma	Lupin
Operating Revenue	33,227.90	28,591.70	34,935.29	14,737.88	29,966.58
Total Income	34,650.70	30,111.40	35,624.79	15,061.79	30,442.31
Total Expenditure	28,088.10	21,334.70	27,850.01	10,911.05	20,428.27
EBITDA	5,139.80	7,257.00	7,085.28	3,826.83	9,538.31
Depreciation	2,119.30	1,724.60	1,859.31	893.20	1,529.37
EBIT	3,020.50	5,532.40	5,225.97	2,933.63	8,008.94
Interest	416.30	510.20	387.88	578.61	452.37
Other Income	1,422.80	1,519.70	689.50	323.91	475.73
Exceptional Items	0.00	-534.80	-105.51	-129.75	-557.91
Profit before Tax	4,027.00	6,007.10	5,422.08	2,549.18	7,474.39
Provision for Tax	857.70	1,514.90	1,709.34	494.07	1,923.38
Profit after Tax	3,169.30	4,492.20	3,712.74	2,055.11	5,551.01

	Dr. Reddy'S Labs	Zydus Lifesciences	Aurobindo Pharma	Mankind Pharma	Lupin
Shareholder's Funds	37,891.50	27,111.40	37,890.97	16,300.34	22,448.27
Minority Interest	38.90	-79.70	1.76	-24.90	-22.18
Non-Current Liabilities	3,145.10	7,112.50	2,580.33	5,011.23	3,200.22
Current Liabilities	16,747.40	15,711.90	18,039.01	6,507.25	12,651.24
Total Liabilities	56,576.70	50,672.60	58,196.15	27,754.83	38,146.06

	Dr. Reddy'S Labs	Zydus Lifesciences	Aurobindo Pharma	Mankind Pharma	Lupin
Non-Current Assets	27,204.00	31,677.20	24,040.45	20,274.65	11,888.82
Current Assets	30,179.30	19,906.10	32,708.75	6,954.20	24,027.38
Total Assets	56,576.70	50,672.60	58,196.15	27,754.83	38,146.06
Total Debt*	7,734.10	11,769.50	7,676.20	6,021.78	5,910.20
Net Current Assets	13,431.90	4,194.20	14,669.74	446.95	11,376.14
Contingent Liabilities	336.14	989.90	1,358.37	924.77	1,094.02

	Dr. Reddy'S Labs	Zydus Lifesciences	Aurobindo Pharma	Mankind Pharma	Lupin
Cash From Operating Activities	5,673.70	2,116.60	5,526.37	3,121.29	7,334.50
Cash Flow from Investing Activities	-6,549.30	-8,296.10	-3,458.61	-196.42	-3,864.59
Cash from Financing Activities	829.00	5,806.90	-1,269.15	-2,952.69	-845.87
Net Cash Inflow / Outflow	-46.60	-372.60	798.61	-27.82	2,624.04

	Dr. Reddy'S Labs	Zydus Lifesciences	Aurobindo Pharma	Mankind Pharma	Lupin
ROCE (%)	13.75	21.39	12.76	13.24	28.86
ROE (%)	8.72	18.78	10.38	13.60	28.32
ROA (%)	5.89	10.03	6.86	7.36	16.43
EBIT Margin (%)	9.09	19.35	14.96	19.91	26.73
Net Margin (%)	9.15	14.92	10.42	13.64	18.23
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Dr. Reddy'S Labs	Zydus Lifesciences	Aurobindo Pharma	Mankind Pharma	Lupin
Revenue Growth (%)	-0.87	21.11	9.09	14.16	28.19
EBIT Growth (%)	-55.06	-8.99	6.91	19.45	77.03
Net Profit Growth (%)	-44.66	-3.14	8.63	8.09	49.13
EPS Growth (%)	-43.29	4.31	11.88	12.27	60.86
Book Value Growth (%)	12.99	13.19	16.04	13.74	30.75

	Dr. Reddy'S Labs	Zydus Lifesciences	Aurobindo Pharma	Mankind Pharma	Lupin
Price / Earnings	31.91	22.95	25.41	43.72	15.00
Price / Book Value	2.69	4.16	2.45	5.58	3.76
Dividend Yield (%)	0.65	0.09	0.24	0.04	0.92
EV/EBITDA	20.14	16.08	13.07	25.60	9.03
Market Cap (₹ Cr)	1,04,763.81	87,643.18	75,689.14	82,801.75	1,05,737.27

	Dr. Reddy'S Labs	Zydus Lifesciences	Aurobindo Pharma	Mankind Pharma	Lupin
Debt to Equity	0.00	0.12	0.02	0.17	0.07
Short term debt to equity ratio	0.16	0.16	0.16	0.04	0.18
Current Ratio	1.80	1.27	1.81	1.07	1.90
Quick Ratio	1.35	0.91	1.15	0.74	1.42
Interest Coverage	10.67	12.77	14.98	5.41	17.52

	Dr. Reddy'S Labs	Zydus Lifesciences	Aurobindo Pharma	Mankind Pharma	Lupin
Debtors to sales (%)	30.47	18.94	20.31	11.74	22.04
Asset Turnover	0.62	0.64	0.65	0.53	0.89
Receivable days	103.79	33.55	33.71	39.93	51.23
Inventory Days	79.94	33.80	59.32	51.78	48.93
Payable days	84.78	149.82	148.20	111.46	205.75
Cash Conversion Cycle	98.95	-82.46	-55.17	-19.75	-105.59

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.